You searched for Gout - Page 51 of 96

Abstract Number: 157 • 2014 ACR/ARHP Annual Meeting
Can We Diagnose Acute Gout without Joint Aspiration? Results of a Prospective Study of 112 Patients Presenting with Acute Arthritis
Pascal Zufferey, Roxana Valcov, Isabelle Fabreguet, Alexandre Dumusc and Alexander So, DAL, RHU/CHUV, Lausanne, Switzerland
Background/Purpose The gold standard for the diagnosis of acute MSU induced arthritis is crystal identification by microscopy after joint aspiration. Alternative diagnostic tools that have…
Abstract Number: 176 • 2014 ACR/ARHP Annual Meeting
Comparative Cardiovascular (CV) Risk and Outcomes Among Patients with Gout, Osteoarthritis (OA), or Both
Svetlana Krasnokutsky¹, Robert T. Keenan², Laura Schneck¹, Craig Tenner³, Helene Strauss⁴, Daria Crittenden⁵, Aaron Lehmann¹ and Michael H. Pillinger¹, ¹NYU School of Medicine, Division of Rheumatology, New York, NY, ²Rheumatology, Duke University, Durham, NC, ³Medicine, NYU School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Amgen, Thousand Oaks, CA
Background/Purpose: Gout is associated with increased CV risk, both dependent on, and independent of traditional CV risk factors. Recent studies suggest that OA, traditionally considered non-inflammatory,…
Abstract Number: 174 • 2014 ACR/ARHP Annual Meeting
Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study
P Sunkureddi¹, E Tóth², J. P Brown³, R Moericke⁴, D. Richard⁵, K Lheritier⁵, A Stancati⁵ and A Kivitz⁶, ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ³CHU de Québec Research Centre and Laval University, Québec, QC, Canada, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Gouty arthritis (GA) patients who experience frequent flares and have comorbidities have limited treatment options. Canakinumab (CAN), a selective, human, anti-interleukin1β monoclonal antibody, has…
Abstract Number: 173 • 2014 ACR/ARHP Annual Meeting
Self-Management Education for Patients with Gout: A Review of Existing Resources
Megan Johnston¹, Gareth Treharne², Peter T. Chapman³ and Lisa K. Stamp⁴, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Psychology, University of Otago, Dunedin, New Zealand, ³Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand, ⁴Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose Inadequate patient self-management education resources may contribute to poor management and outcomes for gout. Patient education resources need to be easy to read and…
Abstract Number: 172 • 2014 ACR/ARHP Annual Meeting
Sleep Apnea and Risk of Incident Gout: A Population-Based Body-Mass Index Matched Cohort Study
Yuqing Zhang¹, Christine Peloquin², Maureen Dubreuil³, Edward Roddy⁴, Na Lu¹, Tuhina Neogi¹ and Hyon K. Choi⁵, ¹Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ³Rheumatology, Boston University Medical Center, Boston, MA, ⁴Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Sleep apnea is common among obese individuals with comorbidities (up to ~30%), a typical profile of gout patients. Since hypoxia associated with sleep apnea…
Abstract Number: 175 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Acute Gouty Arthritis Patients with Chronic Kidney Disease Stage Greater Than or Equal to 3: A Post-Hoc Analysis of 12-Week Data
P Sunkureddi¹, E Tóth², J. P Brown³, A Kivitz⁴, A Stancati⁵, D. Richard⁵, K. Lheritier⁵ and R Moericke⁶, ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ³CHU de Québec Research Centre and Laval University, Québec, QC, Canada, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany
Background/Purpose: Chronic kidney disease (CKD) limits the treatment options in acute gouty arthritis (GA) patients due to intolerance and contraindications to available therapies. Efficacy and…
Abstract Number: 156 • 2014 ACR/ARHP Annual Meeting
Colchicine and the Risk of Acute Cardiovascular (CV) Events Among Gout Patients: The New York Department of Veterans Affairs Retrospective Cohort Study
Daria B. Crittenden^1,2, Jessica N. Kimmel^1,2, Virginia C. Pike^1,2, Rebecca Boas^1,2, Daniel Diaz^1,2, Cilian J. White^1,2, Michael DeBerardine^1,2, Grace Kim^1,2, Pajazit Morina^1,2, Avni Shah^1,2, Binita Shah^2,3, Steven P. Sedlis^2,3, Jeffrey D. Greenberg^2,4, Craig T. Tenner^2,5, Christopher J. Swearingen^1,6, Svetlana Krasnokutsky Samuels^1,2, Bruce N. Cronstein¹ and Michael H. Pillinger^1,2, ¹NYU School of Medicine, Division of Rheumatology, New York, NY, ²VA New York Harbor Health Care System, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, Department of Medicine, New York, NY, ⁶Department of Pediatrics and Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR
Background/Purpose: Gout patients are at increased risk for CV disease, possibly owing to chronic inflammation. Colchicine is commonly used in gout, and inhibits inflammatory cell…
Abstract Number: 155 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis of HLA-B5801 Genotyping in the Treatment of Gout Patients with Chronic Renal Insufficiency in Korea
Dong-Jin Park¹, Kyung-Eun Lee¹, Sung-Hwan Park² and Shin-Seok Lee³, ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose Allopurinol-induced severe cutaneous adverse reactions (SCARs) are relatively rare, but cause high rates of morbidity and mortality. Studies have shown that the HLA-B5801 allele…
Abstract Number: 152 • 2014 ACR/ARHP Annual Meeting
Subclinical Synovial Inflammation in Gout
Priya Chowalloor^1,2, Patrick Cheah³ and Helen I. Keen^1,2, ¹Rheumatology, Royal Perth Hospital, Perth, Australia, ²School of Medicine and Pharmacology, The University of Western Australia, Crawley, Australia, ³Rheumatology, Sir Charles Gairdner Hospital, Nedlands, Australia
Background/Purpose Gout is poorly managed in the community. Long standing poorly controlled gout can lead into progressive destructive arthropathy, decreased quality of life and increased…
Abstract Number: 118 • 2014 ACR/ARHP Annual Meeting
Difficult to Treat Gouty Arthritis Associated with Poor Health Related Quality of Life and High Resource Utilization: Post- Hoc Analysis
Louis Bessette¹, Frédéric Lioté², Carmen Moragues³, Rüdiger Moericke⁴, Zhang Zhiyi⁵, Alberto Ferreira⁶, Pascal Lecomte⁶, Sophia Kessabi⁶, Haijun Tian⁷ and Jasvinder A. Singh^8,9, ¹CHUL, Quebec, QC, Canada, ²Hôpital Lariboisière & University Paris Diderot, Paris, France, ³Hospital Platón, Barcelona, Italy, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵The First Affiliated Hospital of Haerbin Medical University, Haerbin, China, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Mayo Clinic, Rochester, MN, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Difficult-to-treat (DTT) group in the MOTION study included symptomatic refractory gouty arthritis (RGA) patients with ≥3 flares, refractory to NSAIDs/colchicine/steroids or to uric acid…
Abstract Number: 117 • 2014 ACR/ARHP Annual Meeting
Predictors of Gout Flares in a US Managed Care Setting
Robert Jackson¹, Aki Shiozawa², Erin Buysman³, Aylin Altan³, Stephanie Korrer³ and Hyon K. Choi⁴, ¹Global Medical Office, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ²One Takeda Parkway, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ³Health Economics and Outcomes Research, Optum, Eden Prairie, MN, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose Gout is the most common inflammatory arthritis in the US, and acute gout flares are among the most painful events experienced by humans. The…
Abstract Number: 105 • 2014 ACR/ARHP Annual Meeting
Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Robert Morlock¹, Natalia M. Flores², Kathy Annunziata³, J. Chapnick⁴ and Sulabha Ramachandran⁵, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²Kantar Health, Foster City, CA, ³Kantar Health, Princeton, NJ, ⁴Kantar Health, Horsham, PA, ⁵AstraZeneca, Wilmington, DE
Background/Purpose: Gout is caused by chronic high serum uric acid (SUA) levels (i.e., hyperuricemia), which leads to the deposition of monosodium urate crystals in musculoskeletal…
Abstract Number: 46 • 2014 ACR/ARHP Annual Meeting
Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout
Seoyoung C. Kim¹, John D. Seeger², Jun Liu³ and Daniel H. Solomon⁴, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ³Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hyperuricemia and gout are associated with an increased risk of type 2 diabetes (T2D). Xanthine oxidase inhibitors (XOI), allopurinol and febuxostat, are the main…
Abstract Number: 44 • 2014 ACR/ARHP Annual Meeting
Physical Function, Hyperuricemia and Gout in Older Adults
Mara McAdams-DeMarco¹, Bridget Burke², Andrew Law³, Anna Kottgen⁴, Alan N. Baer⁵ and Josef Coresh¹, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Epidemiology, Johns Hopkins, Baltimore, MD, ⁴Renal Division, University Hospital Freiburg, Freiburg, Germany, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The prevalence of gout is higher in older adults than in younger adults and these patients are at risk of physical disability. We sought…
Abstract Number: 45 • 2014 ACR/ARHP Annual Meeting
Body Mass Index Across the Lifespan and Lifetime Incidence of Gout in Men
Allan C. Gelber¹, Lucy Meoni², Michael Klag² and Joseph Gallo², ¹Medicine/ Rheumatology, Johns Hopkins University, Baltimore, MD, ²Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: Gout is the leading cause of inflammatory arthritis in men and is linked to higher levels of body weight and obesity in mid-adult life.…

Can We Diagnose Acute Gout without Joint Aspiration? Results of a Prospective Study of 112 Patients Presenting with Acute Arthritis

Comparative Cardiovascular (CV) Risk and Outcomes Among Patients with Gout, Osteoarthritis (OA), or Both

Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study

Self-Management Education for Patients with Gout: A Review of Existing Resources

Sleep Apnea and Risk of Incident Gout: A Population-Based Body-Mass Index Matched Cohort Study

Efficacy and Safety of Canakinumab in Acute Gouty Arthritis Patients with Chronic Kidney Disease Stage Greater Than or Equal to 3: A Post-Hoc Analysis of 12-Week Data

Colchicine and the Risk of Acute Cardiovascular (CV) Events Among Gout Patients: The New York Department of Veterans Affairs Retrospective Cohort Study

Cost-Effectiveness Analysis of HLA-B5801 Genotyping in the Treatment of Gout Patients with Chronic Renal Insufficiency in Korea

Subclinical Synovial Inflammation in Gout

Difficult to Treat Gouty Arthritis Associated with Poor Health Related Quality of Life and High Resource Utilization: Post- Hoc Analysis

Predictors of Gout Flares in a US Managed Care Setting

Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey

Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout

Physical Function, Hyperuricemia and Gout in Older Adults

Body Mass Index Across the Lifespan and Lifetime Incidence of Gout in Men

Simple Search Results